Frontiers in Oncology (May 2023)

Molecular subtypes and tumor microenvironment infiltration signatures based on cuproptosis-related genes in colon cancer

  • Hongwei Luo,
  • Que Zhang,
  • Xiangchu Liu,
  • Yue Luo,
  • Xing Jiang,
  • Chao Wang,
  • Bin Chen,
  • Qiming He,
  • Yingchun Zhang,
  • Ou Shu,
  • Penggao Dai,
  • Chengcheng He

DOI
https://doi.org/10.3389/fonc.2023.999193
Journal volume & issue
Vol. 13

Abstract

Read online

BackgroundColon cancer is one of the common cancers, and its prognosis remains to be improved. The role of cuproptosis as a newly discovered form of cell death in the development of colon cancer has not been determined.MethodsBased on 983 colon cancer samples in the TCGA database and the GEO database, we performed a comprehensive genomic analysis to explore the molecular subtypes mediated by cuproptosis-related genes. Single-sample gene set enrichment analysis (ssGSEA) was utilized to quantify the relative abundance of each cell infiltrate in the TME. A risk score was established using least absolute shrinkage and selection operator regression (LASSO), and its predictive ability for colon cancer patients was verified to explore its guiding value for treatment.ResultsWe identified two distinct cuproptosis-related molecular subtypes in colon cancer. These two distinct molecular subtypes can predict clinicopathological features, prognosis, TME activity, and immune-infiltrating cells. A risk model was developed and its predictive ability was verified. Compared with patients in the high-risk score group, patients in the low-risk score group were characterized by lower tumor microenvironment score, higher stem cell activity, lower tumor mutational burden, lower microsatellite instability, higher sensitivity to chemotherapeutics, and better immunotherapy efficacy.ConclusionThis study contributes to understanding the molecular characteristics of cuproptosis-related subtypes. We demonstrate a critical role for cuproptosis genes in colon cancer s in the TME. Our study contributes to the development of individualized treatment regimens for colon cancer.

Keywords